Amicus Therapeutics (FOLD) Misses Q2 EPS by 7c
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.40), $0.07 worse than the analyst estimate of ($0.33).
2016 Financial Guidance
Cash, cash equivalents, and marketable securities totaled $214.2 million at June 30, 2016. The Company’s balance sheet was strengthened during the second quarter of 2016 with $57.8 million in net proceeds under the existing at-the-marketing (ATM) financing facility and an additional $30 million in debt under an existing debt facility. Following the second quarter close, the Company raised an additional $39.3 million in net proceeds through the ATM facility and has raised the full $100 million allotted for the ATM facility. The Company expects to remain within the original 2016 net cash spend guidance of between $135 million and $155 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Gold (ABX) Tops Q3 EPS by 4c
- DDR Corp. (DDR) Tops Q3 FFO by 2c
- Murphy Oil (MUR) Tops Q3 EPS by 2c; Guides Q4, FY16 Production
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!